ABITEC announces extension of product portfolio and enters new market
19 September 2016 | By ABITEC Corporation
ABITEC Corporation continues to add new innovations and dosage form applications to their already expansive product portfolio...
List view / Grid view
News
CPHI Worldwide: PCI to share expertise in serialization and safe handling of potent molecules
16 September 2016 | By PCI Pharma Services
Leading pharmaceutical provider PCI Pharma Services will bring its expertize to the stage at CPHI Worldwide (Barcelona, October 4-6 2016) with two Speakers Corner slots at the ICSE Exhibitor Showcase...
Janssen submits EU application for rheumatoid arthritis drug
16 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Sirukumab is a human monoclonal IgG1 kappa antibody that targets the cytokine IL-6, a protein believed to play a role in autoimmune rheumatoid arthritis...
Abeona enrols 5th patient in gene therapy Epidermolysis Bullosa trial
16 September 2016 | By Niamh Louise Marriott, Digital Content Producer
EB-101 is the company's lead gene therapy program for patients suffering with recessive dystrophic epidermolysis bullosa (RDEB), a severe form of...
EC approves Ipsen’s cabometyx to treat advanced RCC following VEGF-targeted therapy
16 September 2016 | By Niamh Louise Marriott,
The European Commission has approved Ibsen’s cabometyx (cabozantinib) 20, 40, 60 mg tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. Cabometyx (cabozantinib) demonstrated significant clinical benefits across all three efficacy endpoints (OS, PFS, ORR) in a phase 3…
Novartis’ long term RRMS drug limits disease progression
16 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Gilenya impacts four key measures of disease activity: relapses, MRI lesions, brain shrinkage (brain volume loss) and disability progression...
Orphan drug designation granted to Boehringer Ingelheim’s systemic sclerosis drug
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Senscis is specifically evaluating nintedanib to understand the disease process and potential benefit of the compound to treat SSc-ILD...
Santhera’s Duchenne muscular dystrophy treatment receives Australian orphan drug designation
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The Australian Therapeutic Goods Administration (TGA) has granted orphan drug designation to Santhera Pharmaceutical’s idebenone (raxone) for the treatment of Duchenne muscular dystrophy (DMD). The product has already received ODD from European, Swiss and US authorities...
Ergomed and Ferrer complete recruitment for Phase IIa insomnia clinical trial
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The effects of lorediplon (5 and 10 mg) are being compared to both placebo and zolpidem. The aim of the study is to evaluate the appropriate effective dose of lorediplon, to further characterise its efficacy on sleep maintenance/sleep quality and to evaluate any next day hangover effects in adult patients…
Major global study reveals new hypertension and blood pressure genes
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The discoveries include DNA changes in three rare genes that have much larger effects on blood pressure in the population than previously seen, providing new insights into the physiology of hypertension and suggesting new targets for treatment...
Coulter Partners places Non-Executive Director for Erytech
8 September 2016 | By Coulter Partners
Coulter Partners was delighted to partner with Erytech Pharma to secure the appointment of Allene M. Diaz to its Board of Directors as a nonvoting member (censeur)...
NICE says coil is more effective than pill as emergency contraception
8 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The coil is the most effective form of emergency contraception for up to 5 days after unprotected sex or within 5 days of expected ovulation...
Vasopharm enrols first patient in phase III traumatic brain injury trial
8 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Vasopharm's ronopternin (VAS203) will be evaluated for its safety and efficacy as the first patient is enrolled into the nostra phase III (NO Synthase in TRAumatic Brain Injury) trial – a clinical study to assess whether the drug can be used as a initial treatment for moderately to severely injured…
Tornado Spectral Systems to exhibit and present at SciX 2016
8 September 2016 | By Tornado Spectral Systems
Leading manufacturer of optical spectrometers and Raman spectroscopy systems to highlight innovative technologies at annual SciX conference...
ADHD market predicted to reach $13.9 billion by 2024
8 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The market for attention deficit hyperactivity disorder (ADHD) across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, is set to experience an increase from approximately $6.1 billion in 2014 to $13.9 billion by 2024, at a compound annual growth rate of 8.5%,…
